NCT07652294Phase 2Enrolling by invitation

Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

Study sponsor: Spyre Therapeutics, Inc. · SYRE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-03-02Estimated
Enrollment · participants645Estimated
Source updated2026-11-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To assess the safety and tolerability of study drug treatment regimens. After: Measure: Percentage of participants who experienced an adverse event.

Check registry source